Arthrogen, an Amsterdam based biopharmaceutical company, is developing local gene therapy for inflammatory diseases, using viral mediated gene transfer. The first target indication is in the field of rheumatic diseases.
Gene therapy could allow life transforming single treatments of chronic diseases with a good safety profile. All over the world gene therapies are tested in clinical trials getting ready to be new promising alternatives for patients.
The Arthrogen therapeutic vectors are derived from natural occurring adeno-associated viruses (AAV) that are not pathogenic in humans. The recombinant viruses are engineered to express therapeutic proteins or to express genes that can knock-down proteins that are involved in the pathogenesis of rheumatic diseases. Arthrogen has completed GMP production of its lead product and is preparing the start of the first clinical trial.
Arthrogen BV was founded in 2005 as a joint venture between the Dubai Bone & Joint Center (DBAJ) in the United Arab Emirates and the Academic Medical Center (AMC) in Amsterdam, the Netherlands.
Arthrogen’s aim is to develop gene therapies to deliver new alternatives to patients while decreasing healthcare costs. The company is based on the premises of the AMC/University of Amsterdam in Amsterdam and has strong tights with both the academic field and the industry.